Your partner for medical collagen

+49 6201 86 358

28.09.2018

Register now for our webshop to view product prices and to place orders online, anytime that is convenient for you.

04.07.2018

Viscofan BioEngineering advances collagenous carrier material as their first medical product to clinical development.
Download press release

22.06.2018

As part of its business development strategy, Viscofan BioEngineering pursues sustainable investments in biomedical research collaborations with public centers. According to the transparency rules established by EFPIA for the biopharmaceutic industry, Viscofan BioEngineering discloses annually the R&D expenses performed with public centers.
In 2017, Viscofan BioEngineering spent 88.000 € for the development of its product pipeline in regenerative medicine in joint projects with university and clinics which was backed by an additional 138.000€ in public funding.

07.05.2018

Presenting the premium collagen hydrolysate COLLinstant®, Viscofan BioEngineering welcomes the nutraceutical industry at booth # I103 at the Vitafoods 2018 in Geneva. Learn more about COLLinstant® and its numerous applications in the food sector and collect a free sample.

This email address is being protected from spambots. You need JavaScript enabled to view it.

02.11.2017

Viscofan BioEngineering portraits the increasing use of collagen as a nutraceutical and explains the advantages of COLLinstant® in a current blog on "Vitafoods Insight".

24.10.2017

Within the framework of the BioRN Annual Conference 2017: “Revolution through convolution – combining medtech, biotech and digital health to promote health science in our region”, corporate manager Dr. Lluís Quintana gave a talk entitled: „Viscofan BioEngineering – von der Wursthülle zum Medizinprodukt – from sausage casing to medical device“.

31.05.2017

Viscofan BioEngineering celebrates new GMP-facility with opening ceremony

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok